152 related articles for article (PubMed ID: 33481399)
1. Outcomes of Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma Based on Patient Age in 964 Eyes of 554 Patients.
Bas Z; Dalvin LA; Tadepalli S; Rao R; Shah A; Leahey AM; Shields CL
Asia Pac J Ophthalmol (Phila); 2021 Jan; 10(4):373-380. PubMed ID: 33481399
[TBL] [Abstract][Full Text] [Related]
2. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
3. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Singh A; Friedman DL; Naduvilath TJ
Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863
[TBL] [Abstract][Full Text] [Related]
4. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
5. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
6. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
7. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
Shields CL; Shields JA; Needle M; de Potter P; Kheterpal S; Hamada A; Meadows AT
Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771
[TBL] [Abstract][Full Text] [Related]
8. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
Shields CL; Shelil A; Cater J; Meadows AT; Shields JA
Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
Demirci H; Eagle RC; Shields CL; Shields JA
Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
[TBL] [Abstract][Full Text] [Related]
10. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
Shields CL; Honavar SG; Shields JA; Demirci H; Meadows AT; Naduvilath TJ
Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for Tumor Recurrence Following Primary Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma in 869 Eyes of 551 Patients.
Dalvin LA; Bas Z; Tadepalli S; Rao R; Vaidya S; Pacheco R; Shields CL
J Pediatr Ophthalmol Strabismus; 2020 Jul; 57(4):224-234. PubMed ID: 32687206
[TBL] [Abstract][Full Text] [Related]
12. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Trans Am Ophthalmol Soc; 2004; 102():35-44; discussion 44-5. PubMed ID: 15747743
[TBL] [Abstract][Full Text] [Related]
13. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation.
Berry JL; Kogachi K; Aziz HA; McGovern K; Zolfaghari E; Murphree AL; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 28221729
[TBL] [Abstract][Full Text] [Related]
14. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
[TBL] [Abstract][Full Text] [Related]
15. Treatment of intraocular retinoblastoma with vincristine and carboplatin.
Rodriguez-Galindo C; Wilson MW; Haik BG; Merchant TE; Billups CA; Shah N; Cain A; Langston J; Lipson M; Kun LE; Pratt CB
J Clin Oncol; 2003 May; 21(10):2019-25. PubMed ID: 12743157
[TBL] [Abstract][Full Text] [Related]
16. Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre.
Shields CL; Bas Z; Tadepalli S; Dalvin LA; Rao R; Schwendeman R; Lally SE; Shields JA; Shah A; Leahey A
Br J Ophthalmol; 2020 Nov; 104(11):1548-1555. PubMed ID: 32051141
[TBL] [Abstract][Full Text] [Related]
17. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.
Gündüz K; Shields CL; Shields JA; Meadows AT; Gross N; Cater J; Needle M
Arch Ophthalmol; 1998 Dec; 116(12):1613-7. PubMed ID: 9869790
[TBL] [Abstract][Full Text] [Related]
18. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma.
Brichard B; De Bruycker JJ; De Potter P; Neven B; Vermylen C; Cornu G
Med Pediatr Oncol; 2002 Jun; 38(6):411-5. PubMed ID: 11984802
[TBL] [Abstract][Full Text] [Related]
19. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Am J Ophthalmol; 2004 Sep; 138(3):329-37. PubMed ID: 15364213
[TBL] [Abstract][Full Text] [Related]
20. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina.
Chantada GL; Fandiño AC; Schvartzman E; Raslawski E; Schaiquevich P; Manzitti J
Pediatr Blood Cancer; 2014 May; 61(5):821-6. PubMed ID: 24243706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
